Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis. - Wikidata - awgldk - TriplyDB

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.

http://www.wikidata.org/entity/Q37661852

about

Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Advances in ovarian cancer therapy.Bevacizumab-associated Bowel Microperforation in a Patient With Neuroblastoma.

P2860

Q47685928-BCED0F4E-A170-4DFA-B340-083ABD4DED51 Q48104995-125CFA6F-66FD-4077-8ACC-00E3DF147BEC Q53735971-4B4301A5-9E9F-41BB-81FE-53F165C923BA

P2860

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.

http://www.wikidata.org/entity/Q37661852

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@en

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@nl

type

label

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@en

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@nl

prefLabel

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@en

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@nl

P1433

Q37661852-CA374C12-E821-4CBE-B0EC-B052B88601CB

P1476

Q37661852-1E911C13-0635-4A3A-AED5-7B439F15C6B5

P2093

Q37661852-0F5E2BB6-78D8-45EB-9839-993F0C6C4021

Q37661852-1E66BA50-2630-4234-AFC3-A631050F2C4D

Q37661852-321583CD-3A61-4ED9-B26F-DFE59D4DAB22

Q37661852-4F02EAD4-087C-4C61-BD47-627959D14A35

Q37661852-535CAEF6-B409-49D3-BE02-07D3AB8D4969

Q37661852-6E0160A2-3F64-4B08-A769-7D3AE9958F34

Q37661852-7B228604-844B-4838-8FAA-FC7025437A58

Q37661852-C56EB299-73D1-4EDF-A367-E44298EBD128

P2860

Q37661852-1E2A8E2B-BEA8-43D8-A5CC-D7AE2D62A970

Q37661852-1EAA08E5-BD93-4CEE-9EC7-5B7D17494EBD

Q37661852-255D80B2-0353-4C9B-AA69-0E191F4D7439

Q37661852-2C742CA0-235C-48D0-A3D2-89CD074B896A

Q37661852-377B394C-3F4B-4910-85DA-F2DF9D7A342C

Q37661852-395DE4CC-A6B5-4AE2-8AF7-F371DD6A6B42

Q37661852-48BCB20E-192F-4E46-9187-A6326B02F798

Q37661852-4C312241-369C-4B3A-9D1E-65B4211E3189

Q37661852-590F6321-5394-422D-9E61-F07591404578

Q37661852-5E6D4B3C-7B97-46F0-BD5C-120BE75C994D

P304

Q37661852-4759BFB8-1CE9-4866-8D29-A25914232EDD

P31

Q37661852-54E8F5E8-09C6-438D-9C04-DDD06C8F5700

P356

Q37661852-ECFD90A9-EB23-4306-A7D6-F0B1E63B076F

P407

Q37661852-42563B47-2C6B-4292-AA1B-C95AD15773D5

P478

Q37661852-D32FB710-16E7-4706-8900-AFF6B421AB42

P577

Q37661852-00ECD71C-3630-4D04-B62A-A4FC3E6ECE79

P698

Q37661852-C5EF686C-59A6-47EB-AD6B-F0271B25D99F

P921

Q37661852-2B94FC46-12C7-4DA3-A567-577739D09B67

Q37661852-F37F79D0-9D2B-43AE-80DC-8AE86CD9A2B4

P932

Q37661852-4EE60443-7D05-4507-91CC-477654763049

P356

P1433

OncoTargets and Therapy

P1476

Antiangiogenic drugs used with ...... arian cancer: a meta-analysis.

@en

P2093

ChengJun Zheng

http://www.w3.org/2001/XMLSchema#string

LongJia Zeng

http://www.w3.org/2001/XMLSchema#string

Lu Yang

http://www.w3.org/2001/XMLSchema#string

Meng Liao

http://www.w3.org/2001/XMLSchema#string

SuYi Yi

http://www.w3.org/2001/XMLSchema#string

Yan Kuang

http://www.w3.org/2001/XMLSchema#string

Yue Zhang

http://www.w3.org/2001/XMLSchema#string

ZhiJuan Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives

Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Integrated genomic analyses of ovarian carcinoma

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Publication and related biases.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

P304

973-984

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S119879

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28255243

http://www.w3.org/2001/XMLSchema#string

P921

P932

5322854

http://www.w3.org/2001/XMLSchema#string